Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — Investor Day (2025)
41 slides from Wuxi Apptec Co., Ltd. Class A's investor day presentation, 2025
Slide 1: WuXi Chemistry: A Global Leading CRDMO Platform
2025 WuXi AppTec Investor Day WuXi Chemistry: A Global Leading CRDMO Platform Minzhang Chen, Ph.D. Co-CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: WuXi Chemistry – a Global Leading CRDMO that Continues to Grow
WuXi Chemistry – a Global Leading CRDMO that Continues to Grow We Care. We Deliver. Research Chemistry STA TIDES Small Molecule Research Small Molecule Development Oligonucleotides, Peptides and and Manufacturing Conjugates Research, Development and Manufacturing 15 23,445 2,550 sites employees clie
Slide 4: Part 1: CRDMO Business Model Drives Sustained High Growth
Part 1 CRDMO Business Model Drives Sustained High Growth 4
Slide 5: Revenue Continues on Upward Trajectory
Revenue Continues on Upward Trajectory 2016-2025 WuXi Chemistry Revenue (RMB ¥ 100 Million) 288.5 291.7 30.5 H2 96.6 140.9 3.5 290.5 261.2 191.9 H1 137.4 163.0 95.9 71.7 44.7 53.0 34.5 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025E non-COVID-19 Commercial Project COVID-19 Commercial Project 5
Slide 6: Strong Revenue Growth in Key Regions
Strong Revenue Growth in Key Regions WuXi Chemistry 2025 H1 Revenue 163.0, Increased by 33.5% vs. 2024 H1 (RMB ￥100 Million) JP & KR & ROW 5.7 YoY +18.5% 15.0 3.5 CN YoY Remain Stable 9.2% % 13.5% 22.0 120.3 EU NA YoY +46.3% YoY +10.6% 73.8% 6
Slide 7: CRDMO Business Model Drives Small Molecule Pipeline Growth
CRDMO Business Model Drives Small Molecule Pipeline Growth, Attains High Molecule Retention “R” 2%↓ 440,000+compounds 14,751 Compounds H1’25 added 412 new molecules to the D&M pipeline 2,881 Preclinical & Phase 1 “D” 3%↑ 368 Phase II 84 Phase III “M” 13%↑ 76 56 Commercial Commercial 7 % growth of mo
Slide 8: CRDMO Model is the Foundation for Sustained Growth
CRDMO Model is the Foundation for Sustained Growth Revenue from Small Molecule Phase III Number of Small Molecule Phase III and Commercial Drugs and Commercial Drugs (Excluding COVID-19 Commercial Projects) (RMB ￥100 Million) Phase III Commercial 50% 160 152 >150% 127 76 H2 107 72 61 50 103.0 89.5 H
Slide 9: Small Molecules Approved by US FDA 2024 - H1 2025
Produced 8 out of 40 Small Molecules Approved by US FDA in 2024 − H1 2025 US FDA New Drug Approvals by Modality (2024 - H1 2025) Peptide Oligonucleotide 1% 4% 13 Cell & Gene Therapy 12% 10 Small Molecule 40 Produced 20% of new drugs 49% 28 approved in 2024 – H1 2025 Biologics - Produced 19% (6 out o
Slide 10: Producing Best-selling Chemically Synthesized Drugs
Producing Best-selling Chemically Synthesized Drugs 4 out of 10 5 out of 10 Best-selling Chemically Forecasted top-selling Synthesized Drugs in 2024 Chemically Synthesized Drugs in 2030 $45+ billion $106+ billion combined global sales of these 4 drugs in 2024 forecasted global sales of these 5 drugs
Slide 11: Producing the Industry's Most Impactful New Therapies
Producing the Industry’s Most Impactful New Therapies 8 10 OUT OF 2024 Molecules of the Year Nominees “We asked the drug discovery community to nominate molecules for our annual Molecules of the Year based on what you found most technically impressive and impactful. These top 10 finalists are select
Slide 12: Securing Fast Growing Market for GLP-1 Agonists
Securing Fast Growing Market for Glucagon-Like Peptide-1 Agonists (GLP-1) Currently Producing 23 GLP-1 Drugs Clinical Stage Peptide Drugs 11 out of 57 WuXi Chemistry is producing 16 GLP-1 small molecule and peptide new drugs currently in Phase II and Clinical Stage Phase III clinical trials, securin
Slide 13: A High-Quality Pipeline Backed by the Trust of Global Innovators
A High-Quality Pipeline Backed by the Trust of Global Innovators 62 out of 213, 29% share of the synthetic drugs global licensing and/or acquisition deals from 2024 - 1H2025 in our pipeline 100% retention rate: all projects stayed through transition of ownership 9 new molecules were quickly moved to
Slide 14: Extending our Leadership Position in China Chemistry-based CRDMO Market
Extending our Leadership Position in China Chemistry-based CRDMO Market 2024 1H – 2025 1H 2023 1H – 2025 1H WuXi Chemistry Revenue vs. 4 Competitors’ Revenue WuXi Chemistry Revenue vs. Combined Revenue of 4 Competitors (RMB ¥ 100 Million) (RMB ¥ 100 Million) +33.5% 2023 1H 16,301 2024 1H 16,301 2024
Slide 15: Part 2: WuXi TIDES: Unlocking Significant New Growth Opportunities
Part 2 WuXi TIDES: Unlocking Significant New Growth Opportunities 15
Slide 16: WuXi TIDES Revenue Continues Unprecedented Growth
WuXi TIDES Revenue Continues Unprecedented Growth WuXi TIDES Revenue (RMB ¥ 100 Million) 80%+ 70% H2 64% 58.0 50.3 34.1 3.0 20.8 7.9 2020 2021 2022 2023 2024 2025E 16
Slide 17: Global Peptide Therapeutics Market Continues Strong Growth
Global Peptide Therapeutics Market Continues to be on Strong Growth Trajectory Key drivers of continued strong peptide market growth: • GLP-1 peptide therapeutics and growing markets for other major indications such as cardiac therapy, immunosuppressants, and gastrointestinal therapy • Fast growth o
Slide 18: Global Oligonucleotide Therapeutics Market: Poised for Substantial Growth
Global Oligonucleotide Therapeutics Market: Poised for Substantial Growth Key drivers of fast oligonucleotide market growth: • Expanding therapeutic applications for CNS, cardiovascular, oncology, sensory organs therapy, particularly for genetic disorders, covering both rare and orphan diseases • Te
Slide 19: WuXi TIDES: an Established Market Leader across CRDMO Value Chain
WuXi TIDES: an Established Market Leader across CRDMO Value Chain Helping to Deliver Vital Therapeutics to Patients Worldwide 19 TIDES Molecules Converted from R to D, accounting for 50% of total new molecules added to TIDES D pipeline in H1 2025 Research Development Manufacturing Compounds delivere
Slide 20: Fast Growing Peptide Production Enabled by Unmatched Capacity
Fast Growing Peptide Production Enabled by Unmatched Capacity Solid Phase Peptide Synthesizer Peptide Product Produced Total Reactor Volume (liter) (kilogram) 58,000+ 100,000+ 36,460 D 41,000 32,000 17,021 6,000 4,352 2,000 4,000 506 711 500 74 2019 2020 2021 2022 2023 2024 2025E 2019 2020 2021 2022
Slide 21: WuXi TIDES Driving More Complex Oligonucleotide and Peptide Conjugate Therapeutics
WuXi TIDES is Driving More Complex Oligonucleotide and Peptide Conjugate Therapeutics Faster to Patients Oligonucleotide - Peptide Conjugate Conjugate Drug Number in WuXi TIDES Pipeline 36 30 Peptide Drug Conjugate 20 13 9 Radionuclide Drug Conjugate 2021 1H 2022 1H 2023 1H 2024 1H 2025 1H • Compreh
Slide 22: Established, Robust Supply Chain for TIDES Molecules
Established, Robust Supply Chain for TIDES Molecules Supports an Efficient Pathway to Patients WuXi TIDES offers building block products at any scale from discovery through commercialization A World-Leading Catalog Platform 58% of oligonucleotide DM clients and Dedicated to “TIDES” Molecules 51% of
Slide 23: Integrated CMC Offering Shortens Timeline to IND
Integrated CMC Offering Shortens Timeline to IND Case Study: Two siRNA-GalNAc INDs Ready in 14 Months 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Analytical Method Development, Validation and Continuous Support Process Development & GalNAc Manufacturing Process Process Optimization Development Demo Batch Pipel
Slide 24: Synergy between API and Drug Product Continues to be a Key Driver
Synergy between API and Drug Product Continues to be a Key Driver of Pipeline Growth TIDES Molecules Using Both API and Drug Product Services 69 57 32 23 4 Jun-30-2021 Jun-30-2022 Jun-30-2023 Jun-30-2024 Jun-30-2025 Number of TIDES molecules using both API and drug product services 24
Slide 25: Part 3: CRDM "O" − Operational Excellence
Part 3 CRDM “O” − Operational Excellence Drives Efficiency and Exceptional Quality 25
Slide 26: Culture of Continuous Improvement: Ongoing Investment in Operational Excellence
Culture of Continuous Improvement: Ongoing Investment in Operational Excellence We continue to employ We have built and Our exemplary quality “WuXi Speed:” Faster plant implemented track record is backed by ramp-up comprehensive digital our operational excellence systems from lab to plant, from R&D
Slide 27: We Continue to Employ "WuXi Speed"
We Continue to Employ “WuXi Speed”: Faster Plant Construction and Ramp-Up Accelerates Products to Patients Plant Ramp-Up Period* (months) Our expansion from 9 plants in 2017 to 33 plants in 2024 has given us a proven playbook for success, ensuring 22.6 First-Time-Right execution on every new plant.
Slide 28: Comprehensive Digital Systems to Achieve "Smart" Operations
We Built and Implemented Comprehensive Digital Systems to Achieve “Smart” Operations 90+ application systems covering all aspects of R&D, Manufacture, and Business Operations etc. 3 Case Studies: Innovative digital systems ensuring high-quality and high-efficiency production Distributed Pyxis Contro
Slide 29: Rapidly Increasing API Production Capacity Across Five Sites
Rapidly Increasing API Production Capacity Across Five Sites Brings More Complexity to Equipment Scheduling 1 site 5 sites API Products Produced (batches) Self-developed Pyxis scheduling system V 1.0 V 2.0 V 3.0 2020 2022 2025 APS 823 H2 Commercial software Advanced Planning & Scheduling 21,362 624
Slide 30: Pyxis: Self-Developed Equipment Scheduling System
Pyxis: Self-Developed Equipment Scheduling System Drives Continuous Improvement of Equipment Utilization Rate Equipment Schedule API Equipment Utilization Rate Continues to Increase Automated scheduling V 3.0 Pyxis 72% V 2.0 68% Intelligent algorithm 66% V 1.0 Real-time management 60% 2020 2022 2024
Slide 31: Highly Automated Control Systems Implemented in all API Plants
Highly Automated Control Systems Implemented in all API Plants Process Controlled by Distributed Control System (DCS) Small molecule ~90% 200,000+ Peptide ~80% DCS I/O points • Built-in process design modules capable of handling complex recipes, procedures, and phases • Highly automated equipment an
Slide 32: Eagle Eye: Self-Developed Digital Material Validation System
Eagle Eye: Self-Developed Digital Material Validation System Minimizes Human Errors on Production Floor Preloaded Data Actual Data from 0.41 8X from Batch Record Production • Material code Eagle Eye • Weight • ….. 0.17 0.08 0.05 • Material specifications such as material code and weight range are pr
Slide 33: Operational Excellence Results in Exemplary Quality Track Record
Operational Excellence Results in Exemplary Quality Track Record 140+ 25 105 successful health authority inspections pre-approval inspections waived by country approvals for since 2009 US FDA and EMA branded drugs Global Quality Inspection Highlights (2024H2 - 2025H1) 5 US FDA 1 EU EMA 2 FDA inspect
Slide 34: Part 4: Investing in China, US, Europe and Singapore
Part 4 Investing in China, US, Europe and Singapore Further Strengthens Our “R” “D” and “M” Network 34
Slide 35: 15 Sites Across the Globe
15 Sites Across the Globe China United States Shanghai Waigaoqiao R D M Shanghai Jinshan D M San Diego, CA D M Tianjin R D Changzhou, Jiangsu D M Middletown, DE D M Wuhan, Hubei R D Changshu, Jiangsu M Chengdu, Sichuan R Taixing #1, Jiangsu M Switzerland Singapore Qidong, Jiangsu R Taixing #2, Jiang
Slide 36: Strengthening Our Global Network
Strengthening Our Global Network Continue to invest in meeting customer demand and in strategic geographic locations • Four new plants have become operational in the past 12 months Taixing, • The facility received its first Pre-Approval Inspection (PAI) by the FDA for commercial China manufacturing
Slide 37: Taixing API Site: Rapid Expansion to Stay Ahead of Market Need
Taixing API Site: Rapid Expansion to Stay Ahead of Market Need July 2024 July 2025 Customer-First Culture Quickly Responding to Demand | Maintaining Operational Excellence 2016 2021 2023 2024 2025 Changzhou Phase I & Ⅱ Changzhou Phase Ⅲ 9 plants | 63 months 6 plants | 24 months Taixing Taixing Phase
Slide 38: Singapore API Site Operational in 2027
Picture taken in July 2025 Singapore API Site Operational in 2027 Small molecules │ Oligonucleotides │ Peptides │ Conjugates Small Molecule TIDES Small Molecule 50-acre campus 7 manufacturing plants planned Groundbreaking 1st small molecule plant 2nd small molecule plant May 2024 operational by Jan
Slide 39: Couvet, Switzerland: Ongoing Investment to Support Growing Global Health Needs
Couvet, Switzerland: Ongoing Investment to Support Growing Global Health Needs Groundbreaking Ceremony for the New Spray Dried Dispersion (SDD) Building Current Expansion Next Phase Expansion Commercial manufacturing capacity 2 billion 250 million 2X PSD-4 spray dryer Parenteral formulation building
Slide 40: Middletown, DE, Campus Operational in Q4 2026
Middletown, DE, Campus Operational in Q4 2026 The new 190-acre North American site to enhance the global supply chain through consistent service and solutions Central Utility Laboratory Drug Product Building Admin Picture taken in Aug. 2025 Operational Timeline Q4 2026 Q4 2027 OSD Manufacturing Ster
Slide 41: WuXi Chemistry
WuXi Chemistry Our unique CRDMO business model remains a key driver of sustainable, long-term growth WuXi TIDES is propelling the next wave of accelerated growth Operational excellence (“O” in CRDMO) continues to deliver superior efficiency and quality Ongoing investment in our global “R”, “D” and “